BeiGene, Ltd.
06160
2022 12 31
2022 12 31
13.09
571 XIVA
2022 12 31
2022 12 31
2022 12 31
2022 12 31
2023
1 2023 2 27
2023 3 31 2022 12 31
1
1995 (Private Securities Litigation
Reform Act of 1995)
CLL
10-Q
2023 2 27
Anthony C. Hooper Margaret Han Dugan
Donald W. Glazer Michael Goller Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
2022
2022 3.39 72.3%
13 97.9%
2022 1.761
101% 2022 5.647 159%
2022 1.022
88% 2022 4.229 66%
(R/R)
(CLL) (SLL)
CLL
3 ALPINE
R/R
CLL/SLL 2022 ASH
2023 2 27
BGNE 06160 688235
2022
(John V. Oyler)
2022
ALPINE (PFS)
(R/R) (CLL)
(SLL)
FDA
R/R CLL/SLL
(Julia Wang)
2022 13
3
2022
2022 3.801 14
2.14 12
2022 3.39 13
1.968 6.34
2022 1.761
5.647 8,760 2.18
2022 1.022
4.229 5,440 2.551
2022
2,770 1.146 2,030
5,880 2021 8
2022 1
2022
2,140 9,430
2,990 8,970
2022 4,110 1.613
2021
2021
1,720 5.423 2021
2022 7,350 2.865
4,850 1.649
2021 8
2022 1
4
2022 78.3%
77.2% 75.3% 74.0%
2022 7.752 29
7.372 25
2022 4.46 16
4.305 15
(CRO) 2022
4,870
6,870 3,000 8,350
2022 3,500
1.393 3,060 1.144
(SG&A) 2022 SG&A 3.29
13 3.065 9.901
SG&A
2022 SG&A 4,320
1.638 3,240 1.264
2022 4.453 0.33
(ADS) 4.29 5.907
0.48 ADS 6.22
2023
2022 20 1.49
ADS 19.43 15 1.21
ADS 15.71 2022 2.239
2021 6.5
2021 4.846
5
2022 12 31 45
2021 12 31 66
2022 3.182 4.453
1.273 1.214
1.104
2021 5.078 5.907
9,270 1.15
34 2021 12
2022 15 20
2.239
3.748
1.324
2021 13 15
1.183 2.774
2.629 36
2021 12
2022 72.3%
97.9%
2022
1.761 5.647
101% 159%
1.253 3.897
124% 237%
(MCL) (WM) (MZL)
4,090 1.503
33% 49%
6
2022
1.022
88% 2022
4.229
66%
4 (NRDL) 9
NRDL 2023 3 1
(NSCLC)
(MSI-H)
(dMMR) (CRC)
(ESCC)
(NPC)
NRDL R/R
2
NRDL
(GCTB)
(BTK)
BTK
65
29
4,800
2023 1 FDA
R/R CLL/SLL
(EC)
(TN) R/R CLL
7
64 (ASH) 3 ALPINE
(IRC)
R/R CLL
SLL PFS
2022 ASH
MZL MAGNOLIA
B
WM
CD20 R/R MZL
(MHRA)
CLL CD20 MZL
2022 1 1 20
34
IgG4 PD-1
Fc
10
31 11,800
(NMPA)
PD-L1 (G/GEJ)
(sBLA)
10
NMPA
(HCC)
sBLA
NSCLC
2023 ASCO RATIONALE-
301(NCT03412773) RATIONALE-305(NCT03777657) RATIONALE-
306(NCT03783442)
PD-L1 G/GEJ (OS)
8
(BGB-A1217) Fc TIGIT
17 1,600
2022 (ESMO-IO)
NSCLC (SCLC)
1 (NCT04047862)
BGB-11417 BCL-2
B
(AML) (MDS)
(MM) BGB-11417
6 350
2022 ASH BGB-11417 CLL
AML MM 1 NCT04883957 NCT04277637 NCT04771130
NCT04973605
BGB-A445 OX40
BGB-A445
(RCC)
2 (NCT05661955)
BGB-B167 CEAx4-1BB
CEA
(CRC)
BGB-A425
(HNSCC) NSCLC
RCC TIM-3
BGB-15025
1(HPK1)
BGB-16673 (CDAC) BTK
B
9
BGB-24714 (SMAC)
BGB-10188
PI3Kδ
BGB-23339 2(TYK2)
Zymeworks zanidatamab HER2
2b (NCT04466891)
Mirati
PD-(L)1
ESCC 2
(NCT05461794)
100 9.3
(GMP) 54,000 2023
10,000
55.9 5.2
6 2023
10
Talk About It: Cancer and
Mental Health
10
2023 (sNDA)
3 ALPINE
R/R CLL/SLL PFS
NMPA CLL/SLL WM sNDA
2023 NMPA
(TGA) CLL sNDA
2023
NMPA
(BLA)
ESCC
2023
2023
TGA
NSCLC ESCC
BLA 2023
(Medsafe)
NSCLC ESCC BLA
MFDS
ESCC BLA
FDA
ESCC BLA
FDA 2023
(EMA)
NSCLC
ESCC EMA 2023
11
MHRA
NSCLC ESCC
ESCC NSCLC
2023 FDA
ESCC
2023 (PMDA)
ESCC BLA
2023
BGB-11417 BCL-2
2023
CLL
TIGIT
2023 2
PD-(L)1 ESCC(NCT04732494)
HCC(NCT04948697)
NSCLC(NCT05014815)
2023 NSCLC 3 AdvanTIG-302
BGB-16673(BTK CDAC)
2023 B 1 NCT05006716
NCT05294731
12
BGB-A445 OX40
2023 1 (NCT04215978)
BGB-15025 HPK1
2023
(NCT04649385)
2023 LBL-007 LAG-3
BGB-A445 NCT05635708 NCT05577702
13
2022 2021
12 31 12 31 1
$4,540,288 $6,624,849
173,168 483,113
845,946 587,605
$6,379,290 $8,535,525
$294,781 $262,400
467,352 558,055
255,887 407,703
293,960 390,362
538,117 629,678
1,995,935 2,402,962
$4,383,355 $6,132,563
14
ADS ADS
12 31 3 12 31 12
2022 2021 1
2022 20211
$339,022 $196,785 $1,254,612 $633,987
41,073 17,194 161,309 542,296
380,095 213,979 1,415,921 1,176,283
73,522 48,545 286,475 164,906
446,023 430,485 1,640,508 1,459,239
328,984 306,501 1,277,852 990,123
188 187 751 750
848,717 785,718 3,205,586 2,615,018
(468,622) (571,739) (1,789,665) (1,438,735)
18,219 (4,482) 52,480 (15,757)
19,438 (10,583) (223,852) 15,904
(430,965) (586,804) (1,961,037) (1,438,588)
14,370 3,874 42,778 19,228
(445,335) (590,678) (2,003,815) (1,457,816)
– – – –
$(445,335) $(590,678) $(2,003,815) $(1,457,816)
$(0.33) $(0.48) $(1.49) $(1.21)
1,348,916,108 1,235,346,414 1,340,729,572 1,206,210,049
ADS $(4.29) $(6.22) $(19.43) $(15.71)
ADS 103,762,778 95,026,647 103,133,044 92,785,388
1
2022 2021
2022 10-K 2.
3.
15
9,000
www.beigene.com.cn
1995 (Private Securities Litigation
Reform Act of 1995)
CLL
10-Q
16
Pharmacyclics LLC
(+86 10)5895-8058 (+86 10)6844-5311
ir@beigene.com media@beigene.com
17